Ernexa Therapeutics (ERNAW) EBITDA (2010 - 2026)

Ernexa Therapeutics has reported EBITDA for 17 years, with the latest figure at -$5.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 104.76% year-over-year to -$5.6 million; the trailing twelve-month figure through Mar 2026 stood at -$12.2 million (up 3.48% YoY), and the FY2025 full-year result was -$9.3 million, up 40.54% from the prior year.
• EBITDA for Q1 2026 stood at -$5.6 million, down from -$2.1 million in the prior quarter.
• The five-year high for EBITDA was -$2.0 million in Q3 2025, with the low at -$13.9 million in Q2 2022.
• Historically, EBITDA has averaged -$5.0 million across 5 years, with a median of -$4.9 million in 2024.
• Annual changes were most pronounced in 2022 — EBITDA surged 90.38% — and 2026, when it slumped 104.76%.
• Ernexa Therapeutics' EBITDA stood at -$4.7 million in 2022, then retreated by 21.7% to -$5.8 million in 2023, then jumped by 53.22% to -$2.7 million in 2024, then grew by 22.36% to -$2.1 million in 2025, then sank by 166.95% to -$5.6 million in 2026.
• The last three EBITDA figures came in at -$5.6 million (Q1 2026), -$2.1 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.